Tagged with medicine

Japan Yoji Yuki, CEO of Japanese regenerative medicine company UniBio, recalls the roots behind the venture and its plant-based technology. He also sets out his ambitions to expand and develop greater manufacturing capabilities in order to meet UniBio’s future ambitions.   What is most important to stress is that there are…

Precision Medicine With Asia covering 60 percent of the world’s population but accounting for just around 30 percent of global pharma spending, it goes without saying that healthcare needs in the region must be addressed effectively, quickly and comprehensively. Who better to accomplish that than the Asian companies on the ground, closest…

Europe In conversation with PharmaBoardroom Christoph Stoller and Adrian Van den Hoven of Medicines for Europe, the association representing the European generics, biosimilar and value-added-medicines industry, highlighted their members’ rapid response to the COVID-19 crisis and why Europe-wide reform is needed to avoid future medicine shortages and strengthen the supply chain.…

Cell & Gene Therapy The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s quest for knowledge, costing USD three billion across 13 years. But even after nearly two decades, we have barely scratched…

Medicines for Europe In the wake of the publication of Medicines for Europe’s Lessons Learned from COVID-19 policy paper, Christoph Stoller & Adrian van den Hoven outline the European generics, biosimilar and value-added-medicines industry’s rapid and comprehensive response to the COVID-19 crisis as well as the potential long-term shifts in European pharmaceutical policy…

China Dr Jin Li explains Chinese firm HitGen’s unique drug discovery technology platform, how its ability to screen billions of molecules has the potential to significantly increase success rates in early drug discovery, and the next steps for the company’s expansion.   By now, we have a platform of over 500…

Korea Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO), explains the basis for Korea’s success in combating the spread of COVID-19, casts light on the future role of precision medicine, and the current hurdles impeding its widespread adoption.   The pandemic, while tragic, has…

Korea Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian patients, explores the company’s expansion plans into China, Japan, and Southeast Asia, and the synergies in their partnerships with big…

Korea Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big Pharma in their oncology projects, and the potential to become a pan-Asian venture in the future.   It is very…

Korea Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in several global M&A deals in the past year with the end goal of finding a combination of assets that will bring value to both investors and patients. With a US manufacturing facility now…

Hong Kong Alex Wong, CEO of Xcelom sat down with PharmaBoardroom to discuss the company’s non-invasive prenatal testing (NIPT) technology and increasing capacity in the field of screening for chromosomal disorders. Wong sheds light on the Asian diagnostics market and unveils his strategy to expand Xcelom’s offering across Asia.   Our pursuit…

Korea Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to shed light on the company’s origins, its collaboration with Big Pharma, and the ease of gaining capital investment for a…